KEGG   DRUG: Givosiran sodium
Entry
D11708                      Drug                                   
Name
Givosiran sodium (JAN);
Givlaari (TN)
Product
GIVLAARI (Alnylam Pharmaceuticals)
Formula
C524H694F16N173O316P43S6.43Na
Exact mass
17280.5941
Mol weight
17288.883
Sequence
(RNA 1) uaagaugaga cacucuuucu ggu
(RNA 2) cagaaagagu gucucaucuu a
  Type
Nucleotide
Remark
Therapeutic category: 3999
ATC code: A16AX16
Chemical structure group: DG03084
Product (DG03084): D11708<JP/US>
Efficacy
Accumulation reduction (neurotoxic intermediates)
  Disease
Acute hepatic porphyria [DS:H00202]
  Type
RNA interference (RNAi) drug
Comment
Treatment of acute hepatic porphyria
Target
ALAS1 [HSA:211] [KO:K00643] (mRNA)
  Pathway
hsa00860  Porphyrin metabolism
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 A ALIMENTARY TRACT AND METABOLISM
  A16 OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
   A16A OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS
    A16AX Various alimentary tract and metabolism products
     A16AX16 Givosiran
      D11708  Givosiran sodium (JAN) <JP/US>
USP drug classification [BR:br08302]
 Genetic, Enzyme, or Protein Disorder: Replacement, Modifiers, Treatment
  Givosiran
   D11708  Givosiran sodium (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
 3  Agents affecting metabolism
  39  Other agents affecting metabolism
   399  Miscellaneous
    3999  Others
     D11708  Givosiran sodium (JAN)
Target-based classification of drugs [BR:br08310]
 Enzymes
  Transferases (EC2)
   Acyltransferases
    ALAS1
     D11708  Givosiran sodium (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11708
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D11708
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11708
Other DBs
PubChem: 405226574
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system